About the book
The advancements of omics fields have enabled various possibilities in drug design enhancements. One of the most significant advances would be the inception of bioinformatics as an independent branch of science that facilitated the deposition of omics data in massive scale or big data, namely with the assistance of the data science-based infrastructure, that would be beneficial for drug design advancement. The advancement in bioinformatics did not evolve independently from the wet laboratory improvement. The field of structural biology and metabolomics has enabled fine-grained biomolecules structural elucidation with X-ray diffraction, NMR, and Cryo-EM sophisticated methods within the assistance of the conventional biochemistry instrumentation such as LC-MS, HPLC, and GC. Moreover, transcriptomics research has enabled the next-generation-sequencing instrument to annotate genomes on a massive scale.
The novel advancement of the epigenomics study also opens the horizon of drug design methods into a massive influx of histone marks information. These aforementioned approaches in omics studies have eventually enriched the existing established ones of proteomics and genomics. As the deposited data is very complex, it is necessary for the bioinformaticians and wet laboratory practicians to collaborate in order to resolve the increasing challenges in drug design. There are drug design challenges in infectious disease that should be resolved; not to mention the problems of ‘civilization diseases’ such as cancer, Alzheimer, cardiovascular, type 2 diabetes, obesity, and others.
In this end, as drug design is becoming more and more multi-disciplinary, it is necessary to ward off the ego-sectoral approach that has fragmented the scientific community as a way to leverage innovation in this field.